Co-Founder and President

Dr. Rodger Novak

Mgmt Rodger Novak new

Dr. Novak is a serial entrepreneur, long-time pharmaceutical and biotechnology senior executive. In 2013, Dr. Novak co-founded CRISPR Therapeutics and served as our Chief Executive Officer from 2013 until December 2017. Since December 2017, Dr. Novak has served as our President. In addition, Dr. Novak has served as a director on our Board of Directors since our founding and as Chairman of our Board of Directors since December 2017. In addition to his roles with the Company, Dr. Novak joined SR One Capital Management, LP, or SR One, in November 2020 as a Venture Partner supporting SR One on new company formation and early-stage investment. Prior to CRISPR Therapeutics, Dr. Novak was Global Head Infectious Diseases at Sanofi, a pharmaceutical company, based in Paris, France. Dr. Novak’s responsibilities included discovery, research and development, and late-stage clinical development of anti-infectives, including diseases of the developing world. In early 2006, Rodger co-founded Nabriva Therapeutics, an antibacterial development company in Vienna, Austria, where he served as Chief Operating Officer until May 2012. Nabriva Therapeutics was a spin-out from Sandoz/Novartis, where Dr. Novak worked as Vice-Head of the Antibiotic Research Institute. Dr. Novak received an M.D. from the Philipps University, Marburg, Germany and was a postdoctoral fellow at the Rockefeller University, the Skirball Institute, and St Jude Children’s Research Hospital. In 2001, Dr. Novak was appointed as tenured Professor for Microbiology at the Vienna Biocenter, Austria. Dr. Novak has authored numerous publications, including articles in Nature, Nature Medicine and Molecular Cell and is a co-inventor of five patents. We believe Dr. Novak’s experience in the biopharmaceutical industry qualifies him to serve on our Board of Directors.

Previous Next

You are now leaving the CRISPR Therapeutics website.

CRISPR Therapeutics is not responsible for the content or availability of third-party sites.